<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01967615</url>
  </required_header>
  <id_info>
    <org_study_id>P2BiTO13</org_study_id>
    <secondary_id>2013-100813</secondary_id>
    <nct_id>NCT01967615</nct_id>
  </id_info>
  <brief_title>P2Y12 Inhibitors Utilization in Bifurcation and Chronic Total Occlusion PCI</brief_title>
  <acronym>P2BiTO</acronym>
  <official_title>P2Y12 Inhibitors Utilization in Bifurcation and Chronic Total Occlusion PCI With Biologically Active Stents (P2BiTO) Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>G. d'Annunzio University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>G. d'Annunzio University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prasugrel and ticagrelor were both associated with a significant reduction in the risk of
      MACE in patients undergoing PCI for an ACS, mostly through a reduced stent thrombosis. The
      1-year relative risk reduction (RRR) of definite of probable stent thrombosis in patients
      receiving a DES were fairly different in TRITON-TIMI 38 and PLATO trials. The incidence of
      &quot;biologically active&quot; stent (DES or BVS) thrombosis is largely variable according to
      different lesion settings. We aim to verify the translation of the postulated different
      reduction in thrombosis rate among various P2Y12 inhibitors (clopidogrel, prasugrel and
      ticagrelor) in a high-risk setting such as the PCI with DES or BVS in CTO and bifurcating
      lesions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients aged 18-80 who underwent PCI of a CTO or bifurcating lesion (all Medina types,
      side branch ≥2 mm) with &quot;biologically active stents&quot; (DES or BVS) between January 2012 and
      december 2014 at participating centers will be deemed eligible to enter the registry.

      In-hospital outcomes will be recorded; all patients discharged alive will be followed up with
      a telephone interview (minimum follow-up 6 months).

      The primary end-point will be the occurrence of a cluster of major adverse cardiovascular
      events at 1 year:

        1. Death from any cause.

        2. Myocardial infarction.

        3. Stent thrombosis, defined as definite, probable or possible following the Academic
           Research Consortium.

      Sample size 3150 patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Death, Myocardial infarction, Stent Thrombosis</measure>
    <time_frame>30 months</time_frame>
    <description>Death from any cause.
Myocardial infarction, defined as an elevation of the creatine kinase MB fraction or cardiac troponins by a factor of 3 or more, or the development of new Q waves in 2 or more contiguous leads at surface ECG7. Levels of total creatine kinase and the creatine kinase MB fraction will be measured in all patients between 12 and 24 hours after PCI.
Stent thrombosis, defined as definite, probable or possible3 following the Academic Research Consortium</description>
  </primary_outcome>
  <enrollment type="Actual">4500</enrollment>
  <condition>Coronary Arteriosclerosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients aged 18-80 undergoing PCI of a CTO or bifurcating lesion (all Medina types,
        side branch ≥2 mm) with &quot;biologically active stents&quot; (DES or BVS) between January 2012 and
        december 2014 at participating centers will be deemed eligible to enter the registry.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18-80 years old

          -  PCI of a CTO or bifurcating lesion (all Medina types, side branch ≥2 mm) with
             &quot;biologically active stents&quot;

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Zimarino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>G. d'Annunzio University</affiliation>
  </overall_official>
  <reference>
    <citation>Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007 Nov 15;357(20):2001-15. Epub 2007 Nov 4.</citation>
    <PMID>17982182</PMID>
  </reference>
  <reference>
    <citation>Cannon CP, Harrington RA, James S, Ardissino D, Becker RC, Emanuelsson H, Husted S, Katus H, Keltai M, Khurmi NS, Kontny F, Lewis BS, Steg PG, Storey RF, Wojdyla D, Wallentin L; PLATelet inhibition and patient Outcomes Investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010 Jan 23;375(9711):283-93. doi: 10.1016/S0140-6736(09)62191-7. Epub 2010 Jan 13.</citation>
    <PMID>20079528</PMID>
  </reference>
  <reference>
    <citation>Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007 May 1;115(17):2344-51.</citation>
    <PMID>17470709</PMID>
  </reference>
  <reference>
    <citation>Steg PG, Harrington RA, Emanuelsson H, Katus HA, Mahaffey KW, Meier B, Storey RF, Wojdyla DM, Lewis BS, Maurer G, Wallentin L, James SK; PLATO Study Group. Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation. 2013 Sep 3;128(10):1055-65. doi: 10.1161/CIRCULATIONAHA.113.002589. Epub 2013 Jul 30.</citation>
    <PMID>23900047</PMID>
  </reference>
  <reference>
    <citation>Valenti R, Vergara R, Migliorini A, Parodi G, Carrabba N, Cerisano G, Dovellini EV, Antoniucci D. Predictors of reocclusion after successful drug-eluting stent-supported percutaneous coronary intervention of chronic total occlusion. J Am Coll Cardiol. 2013 Feb 5;61(5):545-50. doi: 10.1016/j.jacc.2012.10.036. Epub 2012 Dec 26.</citation>
    <PMID>23273395</PMID>
  </reference>
  <reference>
    <citation>Zimarino M, Corazzini A, Ricci F, Di Nicola M, De Caterina R. Late thrombosis after double versus single drug-eluting stent in the treatment of coronary bifurcations: a meta-analysis of randomized and observational Studies. JACC Cardiovasc Interv. 2013 Jul;6(7):687-95. doi: 10.1016/j.jcin.2013.03.012. Epub 2013 Jun 14. Review.</citation>
    <PMID>23769650</PMID>
  </reference>
  <reference>
    <citation>Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Writing Group on the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction, Thygesen K, Alpert JS, White HD, Jaffe AS, Katus HA, Apple FS, Lindahl B, Morrow DA, Chaitman BA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasché P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S; ESC Committee for Practice Guidelines (CPG). Third universal definition of myocardial infarction. Eur Heart J. 2012 Oct;33(20):2551-67. doi: 10.1093/eurheartj/ehs184. Epub 2012 Aug 24.</citation>
    <PMID>22922414</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2013</study_first_submitted>
  <study_first_submitted_qc>October 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2013</study_first_posted>
  <last_update_submitted>October 26, 2017</last_update_submitted>
  <last_update_submitted_qc>October 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>G. d'Annunzio University</investigator_affiliation>
    <investigator_full_name>Raffaele De Caterina</investigator_full_name>
    <investigator_title>MD/PhD</investigator_title>
  </responsible_party>
  <keyword>PCI,</keyword>
  <keyword>CTO,</keyword>
  <keyword>bifurcation,</keyword>
  <keyword>clopidogrel,</keyword>
  <keyword>prasugrel,</keyword>
  <keyword>ticagrelor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

